Printer Friendly

OIA, INC. ENTERS NASDAQ SYSTEM

 OIA, INC. ENTERS NASDAQ SYSTEM
 SALEM, N.H., Oct. 14 /PRNewswire/ -- OIA, Inc., today announced the


company will begin trading on the small cap listing of NASDAQ with the symbol BREL effective Oct. 15. At the company's annual meeting, to be held Oct. 29, 1992, stockholders will vote on several proposals including one to change the name of the company to Biorelease Corp.
 OIA's listing on NASDAQ will enable stockbrokers to provide real- time, last-sale prices and volume information on OIA stock for their clients throughout the trading day. OIA also will be included in the newspaper stock table, which shows high, low and closing prices for NASDAQ securities.
 "We expect that the listing of OIA stock on NASDAQ will facilitate trading in our company's stock, as well as increase OIA's visibility to investors," commented P. Calvin Maybury, Ph.D., OIA, Inc. president and chief executive officer.
 OIA, Inc. is initially dedicated to commercializing proprietary cell-culture additives and developing applications of its chondroitin sulfate sustained release drug delivery technology. The company has its headquarters in Salem, N.H.
 -0- 10/14/92
 /CONTACT: Dr. R. Bruce Reeves, of OIA, Inc., 603-893-7300, or Lynne H. Brum of Feinstein Partners, Inc., 617-577-8110, for OIA, Inc./
 (BREL) CO: OIA Inc. ST: New Hampshire IN: MTC SU: OFR


TM -- NE008 -- 9805 10/14/92 11:22 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 14, 1992
Words:223
Previous Article:GEODYNAMICS CORP. ANNOUNCES FIRST QUARTER OPERATING RESULTS
Next Article:SC BANCORP POSTS THIRD QUARTER PROFIT
Topics:


Related Articles
BIOSTAR RECEIVES NIH GRANT TO ENHANCE OIA TECHNOLOGY COMPANY'S RAPID TEST FOR CHLAMYDIA TO RESEARCH NEW SAMPLE MATERIAL
Biota Holdings Selects BioStar to Develop Influenza Diagnostic
Cortech and BioStar Terminate Merger
BioStar Announces Technical Advances to Its Proprietary OIA Technology; Boulder Firm Makes Exclusive Claim To New Technology
BioStar Announces Major Diagnostic Program with Agouron.
Biota and Boehringer Ingelheim Complete US$102 Million License for HCV Program.
RSV Drug Starts Phase Ia Clinical Trials.
Biota Delivers Profit After Tax of US$17.2m.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters